| Dr Gary Bradley Sherrill, MD | |
|
501 N Elam Ave, Greensboro, NC 27403-1118 | |
| (336) 832-1100 | |
| Not Available |
| Full Name | Dr Gary Bradley Sherrill |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 35 Years |
| Location | 501 N Elam Ave, Greensboro, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003869413 | NPI | - | NPPES |
| 10304 | Other | NC | PARTNERS MEDICARE |
| 57371 | Other | NC | MEDCOST |
| 75762 | Other | NC | BCBS NC |
| 5889067 | Other | NC | AETNA |
| 8975762 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 36633 (North Carolina) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 36633 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice And Palliative Care Of Greensboro | Greensboro, NC | Hospice |
| Moses H. Cone Memorial Hospital, The | Greensboro, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Moses H Cone Memorial Hospital Operating Corporation | 6204744600 | 496 |
News Archive
More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.
An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to speed up the work and accidentally contaminated the samples, the Centers for Disease Control and Prevention reported Friday.
Stryker Corporation's Orthopaedics' division today announced at the American Academy of Orthopaedic Surgeons Conference that its recent FDA-monitored Investigational Device Exemption study found no statistical difference in clinical outcomes between its mobile bearing and traditional fixed bearing knee systems. In contrast, Stryker continues to be very pleased with the success of its fixed bearing Triathlon Knee System with X3 Advanced Bearing Technology, which offers significant advantages over mobile bearing knees on wear rates and overall value.
Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
› Verified 4 days ago
| Entity Name | The Moses H Cone Memorial Hospital Operating Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356372064 PECOS PAC ID: 6204744600 Enrollment ID: O20031204000940 |
News Archive
More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.
An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to speed up the work and accidentally contaminated the samples, the Centers for Disease Control and Prevention reported Friday.
Stryker Corporation's Orthopaedics' division today announced at the American Academy of Orthopaedic Surgeons Conference that its recent FDA-monitored Investigational Device Exemption study found no statistical difference in clinical outcomes between its mobile bearing and traditional fixed bearing knee systems. In contrast, Stryker continues to be very pleased with the success of its fixed bearing Triathlon Knee System with X3 Advanced Bearing Technology, which offers significant advantages over mobile bearing knees on wear rates and overall value.
Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
› Verified 4 days ago
| Entity Name | Moses Cone Affiliated Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346474103 PECOS PAC ID: 3779635396 Enrollment ID: O20090713000512 |
News Archive
More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.
An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to speed up the work and accidentally contaminated the samples, the Centers for Disease Control and Prevention reported Friday.
Stryker Corporation's Orthopaedics' division today announced at the American Academy of Orthopaedic Surgeons Conference that its recent FDA-monitored Investigational Device Exemption study found no statistical difference in clinical outcomes between its mobile bearing and traditional fixed bearing knee systems. In contrast, Stryker continues to be very pleased with the success of its fixed bearing Triathlon Knee System with X3 Advanced Bearing Technology, which offers significant advantages over mobile bearing knees on wear rates and overall value.
Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gary Bradley Sherrill, MD Po Box 14878, Greensboro, NC 27415-4878 Ph: (336) 547-1877 | Dr Gary Bradley Sherrill, MD 501 N Elam Ave, Greensboro, NC 27403-1118 Ph: (336) 832-1100 |
News Archive
More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects.
An investigation into the mistaken shipment of deadly bird flu virus from a government laboratory earlier this year found that a scientist took shortcuts to speed up the work and accidentally contaminated the samples, the Centers for Disease Control and Prevention reported Friday.
Stryker Corporation's Orthopaedics' division today announced at the American Academy of Orthopaedic Surgeons Conference that its recent FDA-monitored Investigational Device Exemption study found no statistical difference in clinical outcomes between its mobile bearing and traditional fixed bearing knee systems. In contrast, Stryker continues to be very pleased with the success of its fixed bearing Triathlon Knee System with X3 Advanced Bearing Technology, which offers significant advantages over mobile bearing knees on wear rates and overall value.
Proteins responsible for controlling levels of iron in the body also play an important role in combatting infection, according to a study published today in Cell Host & Microbe.
OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.
› Verified 4 days ago
Dr. Olugbemiga Ebenezer Jegede, M.D Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 201 E Wendover Ave, Greensboro, NC 27401 Phone: 336-832-4444 Fax: 336-832-4445 | |
Yan Feng, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 501 N Elam Ave, Greensboro, NC 27403 Phone: 336-832-1100 | |
Edwin Aziegbe Avbuere, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3231 Yanceyville Street, Greensboro, NC 27405 Phone: 336-358-1528 Fax: 336-358-1582 | |
Dr. Jay Krishnavadan Patel, MB.CHB Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 309 New St, Carolina Kidney Associates, Greensboro, NC 27405 Phone: 336-379-9708 Fax: 336-553-2085 | |
Gayatri A Acharya, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3200 Northline Ave Ste 250, Greensboro, NC 27408 Phone: 336-273-7900 | |
Murali Ramaswamy, MD FAAFP Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 520 N Elam Ave, Greensboro, NC 27403 Phone: 336-547-1801 Fax: 336-547-1828 |